Longeveron (LGVN) said Tuesday it has been granted Small or Medium-sized Enterprise status by the European Medicines Agency, providing the company with regulatory and financial benefits as it advances drug development efforts in Europe.
The EMA's SME program is designed to support smaller companies developing medicinal products by offering incentives and assistance throughout the regulatory process, including before and after product approval, the biotechnology company said.
Price: $0.77, Change: $+0.01, Percent Change: +1.86%